Recent 8-K filings for NWBO
Highest-materiality recent filing
Northwest Biotherapeutics announces $5M convertible note and $50M standby equity facility
- Entered $5M convertible promissory note with Yorkville, 13-month term, 7% original issue discount, no interest.
- Conversion at small discount to market price; limited to 1/6 of note per month unless conversion price above $0.315.
-
Total consideration: ~$1.9M (£1.4M) purchase price plus ~$8.3M in accounts payable to Advent; unpaid balance accrues 7.5% interest.
-
NWBO shareholders OK share increase to 2.6B, elect Pat Sarma
Authorized common shares increased from 1.7B to 2.6B; 89.65% of votes cast in favor.
-
NWBO enters $5M convertible note with Yorkville for Sawston facility
Promissory note of $5M with YA II PN, Ltd. (Yorkville) for 12 months, no payments due until maturity.
-
Northwest Biotherapeutics settles shareholder litigation over 2020 options; insurers to pay $2.25M
Settlement resolves Delaware Chancery litigation over 2020 option awards to management and directors.
-
Northwest Biotherapeutics announces $5M convertible note and $50M standby equity facility
Entered $5M convertible promissory note with Yorkville, 13-month term, 7% original issue discount, no interest.
-
Northwest Biotherapeutics enters $5M convertible note with 11% interest, 24-month maturity
Company entered $5,000,000 convertible note with an unrelated shareholder on Oct 31, 2024.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.55 · Most common event debt